Sana Biotechnology, Inc.

NASDAQ:SANA

Biotechnology

Healthcare
$1.85 +1.23%

+$0.04 today

Market cap
$554.32M
Beta
2.16
P/E (TTM)
-3.5
EPS (TTM)
-$0.87
52W Low $2.58High $6.55

Volume 2.66M

Average 3.76M

SANA Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Sana Biotechnology, Inc.NASDAQ: SANA

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 276.86M shares rose 16.5% year over year, ahead of the +9.0% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 9.3% from the prior quarter. Over 3 fiscal years it compounded at +10.4% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +16.5% holds above the trailing-twelve-month pace of +9.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
276.86M+9.3% QoQ
Last fiscal yearDec 2025
253.23M+9.7% YoY
LTMMar 2026
257.25M+9.0% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+16.5%——
1 year+9.7%——
3-year CAGR+10.4%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
253.23M USD
Year-over-year change
+9.7%
4-year CAGR
+11.1%

Weighted Avg Shares vs competitors

How SANA compares with its peers on the latest reported figures

  • SANA's LTM Mar 2026 weighted avg shares of 257.25M shares is the highest of the 11 companies compared; the peer median is 99.03M shares.
  • Its year-over-year change of +9.0% is the 6th highest of 11, against a peer median of +8.9%.
  • Over three fiscal years its annual growth of +10.4% compares with a peer median of +12.1%.
SANA Competitors Peer median
Weighted Avg Shares for SANA and competitors
Company Period LTM YoY 3-year CAGR
SANASana Biotechnology, Inc.LTM Mar 2026257.25M +9.0%+10.4%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026225.47M +9.3%+15.5%
LEGNLegend Biotech CorporationLTM Sep 2026185.87M +1.7%+5.0%
FATEFate Therapeutics, Inc.LTM Mar 2026119.09M +1.0%+7.1%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026110.2M +9.3%+12.1%
BEAMBeam Therapeutics Inc.LTM Jun 2026103.26M +16.4%+12.2%
CRSPCRISPR Therapeutics AGLTM Sep 202694.81M +8.4%+5.0%
IPSCCentury Therapeutics, Inc.LTM Mar 202686.45M +4.3%+14.4%
CGEMCullinan Therapeutics, Inc.LTM Mar 202659.11M +2.4%+9.3%
ATRAAtara Biotherapeutics, Inc.LTM Mar 202613.1M +49.4%+45.4%
DTILPrecision BioSciences, Inc.LTM Mar 202612.13M +61.6%+63.6%
Peer median (excluding SANA) 99.03M+8.9%+12.1%

Competitors are the stored peer set for SANA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue000012.75M
Gross Profit0000(12.75M)
Gross Margin—————
Research & Development306.5M201M219.84M208.68M131.98M
Selling, General & Admin50.41M71.56M73.3M64.04M44.3M
Operating Expenses356.91M272.56M293.14M272.72M178.21M
Depreciation & Amortization11.07M15.63M24.56M17.39M12.75M
EBITDA(344.86M)(253.85M)(258.7M)(249.37M)(231.42M)
EBITDA Margin—————
Operating Income(356.91M)(272.56M)(293.14M)(272.72M)(190.96M)
Operating Margin—————
Interest Income676K3.76M9.94M10.47M3.85M
Interest Expense00000
Other Income / Expenses981K3.09M9.89M5.96M(53.21M)
Income Before Tax(355.93M)(269.48M)(283.26M)(266.76M)(244.17M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(355.93M)(269.48M)(283.26M)(266.76M)(244.17M)
Net Margin—————
EPS (Basic)(2.14)(1.43)(1.46)(1.16)(0.96)
EPS (Diluted)(2.14)(1.43)(1.46)(1.16)(0.96)
Weighted Avg Shares166.43M188.34M194.54M230.89M253.23M
Weighted Avg Shares (Diluted)166.43M188.34M194.54M230.89M253.23M

Sana Biotechnology, Inc.

NASDAQ:SANA

Intrinsic Alpha fair value

Locked

Current Price

$1.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.